Comparative Pharmacology
Head-to-head clinical analysis: DECADRON LA versus DEXAMETHASONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECADRON LA versus DEXAMETHASONE.
DECADRON-LA vs DEXAMETHASONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to produce anti-inflammatory and immunosuppressive effects; suppresses migration of polymorphonuclear leukocytes, reverses increased capillary permeability, and reduces cytokine production.
Agonist at glucocorticoid receptors, leading to altered gene expression and suppression of inflammatory mediators.
Dexamethasone acetate (DECADRON-LA) 8-16 mg intramuscularly every 1-3 weeks; adjust based on response and tolerance.
0.5-24 mg/day oral, IV, IM in 2-4 divided doses; anti-inflammatory: 0.75-9 mg/day; multiple myeloma: 40 mg oral/IV once daily on days 1-4, 9-12, 17-20 every 28 days.
None Documented
None Documented
Clinical Note
moderateDexamethasone + Digoxin
"Dexamethasone may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDexamethasone + Digitoxin
"Dexamethasone may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDexamethasone + Deslanoside
"Dexamethasone may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDexamethasone + Acetyldigitoxin
"Dexamethasone may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 3-4 hours for dexamethasone, but due to the acetate ester in Decadron-LA, absorption is prolonged, leading to an extended duration of action. The apparent half-life after intramuscular administration is about 3-4 days (72-96 hours) due to slow release from the injection site.
Terminal elimination half-life 3-4 hours; clinically, duration of HPA suppression may exceed 24 hours due to prolonged receptor binding.
Renal (<5% unchanged), hepatic metabolism with inactive metabolites excreted renally and fecally; urine and bile are minor routes. Exact % not specified for Decadron-LA (dexamethasone acetate), but dexamethasone is predominantly metabolized and metabolites are excreted renally (~80% of dose) and fecally (~20%).
Primarily renal (65-80% as unchanged drug); minor biliary/fecal (<10%).
Category C
Category D/X
Corticosteroid
Corticosteroid